Shuttle Pharmaceuticals Holdings Business Summary

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is a clinical-stage biotechnology firm that has recently undergone a fundamental strategic pivot from a traditional single-asset clinical model to an AI-enabled drug discovery platform. Historically focused on developing radiation sensitizers to enhance cancer treatment outcomes, the company announced in early 2026 the discontinuation of clinical trials for its lead candidate, Ropidoxuridine (IPdR), to prioritize its newly acquired Molecule.ai platform. This $10 million acquisition shifts the company’s revenue potential toward licensing, molecular evaluation services, and autonomous drug discovery workflows using large language models (LLMs). As of February 2026, the company remains in a pre-revenue stage, reporting a preliminary 2025 net loss of approximately $10.9–$12.1 million. In the competitive landscape of oncology-focused small-caps, Shuttle Pharmaceuticals contends with players like Longeveron (LGVN), BioAtla (BCAB), and Phio Pharmaceuticals (PHIO), distinguishing itself through its aggressive integration of agentic AI to accelerate early-stage therapeutic identification. The company’s leadership is currently managed by a specialized executive team and a board with deep ties to Georgetown University Medical Center. Christopher Cooper serves as the Interim Chief Executive Officer, bringing over 27 years of experience in finance and corporate restructuring across the technology and resource sectors. He is supported by Yuying Liang, who was appointed Chief Financial Officer in January 2026, succeeding Cooper in that role. The scientific foundation of the firm remains anchored by Co-Founder and Chief Scientific Officer Anatoly Dritschilo, M.D., a renowned radiation oncologist and former Chairman of Radiation Medicine at Georgetown. The board of directors includes Chairman of the Audit Committee George Scorsis and Adam Chambers, principal of Bowery Consulting Group, which provides critical revolving loan facilities to the firm. This leadership structure is designed to balance Dritschilo’s clinical pedigree with the business acumen required to navigate the company's transition into the AI-driven pharmaceutical market.